For Vertex these days, it’s all about the launches of three new products—sickle cell disease gene therapy Casgevy, the ...

Vertex (VRTX) stock was trading largely flat post-market after the company released its Q4 earnings report and issued 2025 ...

The company posted quarterly adjusted earnings of $3.48 per share which missed the analyst consensus estimate of $4.03 per ...

Vertex Pharmaceuticals (VRTX) stock gets an upgrade from Canaccord Genuity after its Q4 2024 results on Tuesday, Read more here.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

High school basketball: Scores for boys’ and girls’ games across the Southland on Wednesday, Feb. 12. High school basketball: Scores for boys’ and girls’ games across the Southland on ...

CNBC Select will update as changes are made public. With a high-yield savings account, you can get a solid interest rate and your money grows even faster thanks to compound interest — which lets ...

Commissions do not affect our editors' opinions or evaluations. The best high-yield savings account is Capital One 360 Performance Savings Account™, earning the top rating of 5.0 stars in our study.

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2024 investor letter. A copy of the ...

Scotiabank (TSX:BNS) analyst Greg Harrison updated the price target for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a $121 billion market cap biotechnology company, to $450, up from the ...

Scotiabank raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $450 from $433 and keeps a Sector Perform rating on the shares. The company had a strong Q4, with revenue beating ...